Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals, Inc. (ATNM) Healthcare & Pipeline Overview

Actinium Pharmaceuticals, Inc. pioneers targeted radiotherapies for cancers, focusing on bone marrow transplant conditioning and adoptive cell therapies. Their lead candidate, I-131 apamistamab (Iomab-B), targets relapsed or refractory acute myeloid leukemia, positioning them in the competitive biotechnology landscape with a focus on innovative cancer treatments.

What Is the Investment Thesis for ATNM?

Actinium Pharmaceuticals presents a high-risk, high-reward investment opportunity centered on its targeted radiotherapy pipeline. The primary value driver is the successful completion and commercialization of I-131 apamistamab (Iomab-B), currently in Phase III trials for relapsed or refractory AML. Positive trial results could lead to accelerated regulatory approval and market adoption, addressing a significant unmet need in BMT conditioning. Further value lies in Actinium's collaborations and preclinical programs targeting various cancer targets. However, the company's negative profit margin of -37652.2% underscores the significant financial risks associated with clinical-stage biopharmaceutical companies. Investment hinges on the successful clinical development and regulatory approval of its lead candidate and the ability to secure additional funding or partnerships to support ongoing research and development.

Based on FMP financials and quantitative analysis

ATNM Key Highlights

• Lead product candidate I-131 apamistamab (Iomab-B) is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia.
• Gross Margin is 100.0%.
• Market capitalization of $30.20M.
• Collaborations with Astellas Pharma, Inc., EpicentRx, Inc., and AVEO Oncology to expand therapeutic applications.
• Beta of -0.30 indicates a lower volatility compared to the market.

Who Are ATNM's Competitors?

ATNM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ATNM's Key Strengths?

• Proprietary technology in targeted radiotherapy.
• Lead product candidate in Phase III clinical trials.
• Collaborations with reputable institutions and companies.
• Experienced management team.

What Are ATNM's Weaknesses?

• Clinical-stage company with no currently approved products.
• High cash burn rate and reliance on external funding.
• Negative profit margin.
• Small number of employees.

What Could Drive ATNM Stock Higher?

• Data readout from the Phase III clinical trial of I-131 apamistamab (Iomab-B) in elderly relapsed or refractory AML.
• Progress in the Phase I study with a CD19-targeted CAR T-cell therapy.
• Advancement of preclinical programs targeting CD45, CD33, CD38, CD47, HER2, and HER3.

What Are the Key Risks for ATNM?

• Financial-distress signal — its Altman Z-Score of -13.12 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $1.9M recently.
• Failure to secure regulatory approval for I-131 apamistamab (Iomab-B).
• Clinical trial failures.
• Competition from other cancer therapies.
• Inability to secure additional funding.

What Are the Growth Opportunities for ATNM?

• Expansion into new therapeutic areas: Actinium has the opportunity to expand its pipeline by developing targeted radiotherapies for other cancer types beyond AML. By leveraging its expertise in isotope-based therapies and targeting different cancer-specific antigens, Actinium can address a broader market and reduce its reliance on a single product. The market for targeted cancer therapies is projected to reach $150 billion by 2030, offering substantial growth potential.
• Strategic partnerships and collaborations: Actinium can accelerate its drug development efforts and expand its market reach through strategic partnerships and collaborations. Collaborating with larger pharmaceutical companies or specialized biotechnology firms can provide access to additional funding, expertise, and resources. The company's existing collaborations with Astellas Pharma, EpicentRx, and AVEO Oncology demonstrate its ability to forge such partnerships, which can drive future growth.
• Advancement of preclinical programs: Actinium's preclinical programs targeting CD45, CD33, CD38, CD47, HER2, and HER3 represent significant growth opportunities. These programs have the potential to yield new drug candidates for both targeted conditioning prior to cell and gene therapies and cancer therapeutics. Successful advancement of these programs into clinical trials could create substantial value for the company.
• Geographic expansion: Actinium can expand its market presence by seeking regulatory approval and commercializing its products in new geographic regions. The company's initial focus is on the US market, but expanding into Europe, Asia, and other regions could significantly increase its revenue potential. The global market for cancer therapies is expected to reach $250 billion by 2030, with significant growth opportunities in emerging markets.
• Combination therapies: Actinium can explore the potential of combining its targeted radiotherapies with other therapeutic modalities, such as chemotherapy, immunotherapy, and targeted therapies. Combination therapies have the potential to improve treatment outcomes and overcome resistance mechanisms. By developing and testing combination regimens, Actinium can enhance the efficacy of its products and expand their market applications.

What Opportunities Does ATNM Have?

• Successful completion of Phase III trials and regulatory approval of Iomab-B.
• Expansion into new therapeutic areas and geographic markets.
• Advancement of preclinical programs.
• Strategic partnerships and collaborations.

What Threats Does ATNM Face?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from other cancer therapies.
• Inability to secure additional funding.

What Are ATNM's Competitive Advantages?

• Proprietary technology in targeted radiotherapy.
• Patent protection for its lead product candidate, I-131 apamistamab (Iomab-B).
• Clinical trial data demonstrating efficacy and safety.
• Established collaborations with leading cancer centers and pharmaceutical companies.

What Does ATNM Do?

Actinium Pharmaceuticals, Inc., founded in 2000 and based in New York City, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancers, particularly those requiring bone marrow transplant (BMT) or other adoptive cell therapies. The company's primary focus is on targeted radiotherapies, utilizing isotopes like Actinium-225, Iodine-131, and Lutetium-177 to deliver radiation directly to cancer cells. Their lead product candidate, I-131 apamistamab (Iomab-B), is currently in a pivotal Phase III clinical trial, evaluating its effectiveness as a conditioning regimen prior to BMT in elderly patients with relapsed or refractory acute myeloid leukemia (AML). Actinium also has a Phase I study underway with a CD19-targeted CAR T-cell therapy in collaboration with Memorial Sloan Kettering Cancer Center. Beyond Iomab-B, Actinium has preclinical development programs targeting CD45, CD33, CD38, CD47, HER2, and HER3. These programs aim to develop targeted conditioning agents for cell and gene therapies, as well as cancer therapeutics for single-agent or combination use. Actinium has established collaborations with Astellas Pharma, Inc. to develop theranostics for solid tumor indications, EpicentRx, Inc. for a CD47 immunotherapy targeted radiotherapy, and AVEO Oncology for developing a HER3 targeting ARC for solid tumors.

What Products and Services Does ATNM Offer?

• Develop targeted radiotherapies for cancer treatment.
• Focus on therapies for bone marrow transplant (BMT) conditioning.
• Develop adoptive cell therapies.
• Utilize isotopes like Actinium-225, Iodine-131, and Lutetium-177.
• Target cancer antigens such as CD45, CD33, CD38, CD47, HER2, and HER3.
• Conduct clinical trials to evaluate the safety and efficacy of their therapies.
• Collaborate with other companies to develop and commercialize new therapies.

How Does ATNM Make Money?

• Develop and patent novel targeted radiotherapies.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Commercialize approved therapies directly or through partnerships.

What Industry Does ATNM Operate In?

Actinium Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Targeted radiotherapies represent a promising area within oncology, offering the potential for more effective and less toxic treatments compared to traditional chemotherapy. Actinium's focus on BMT conditioning and adoptive cell therapies positions it within a niche market with significant unmet needs. Success depends on demonstrating clinical efficacy and safety, navigating regulatory hurdles, and securing sufficient funding to support ongoing development efforts.

Who Are ATNM's Key Customers?

• Hospitals and cancer centers that perform bone marrow transplants.
• Oncologists who treat patients with acute myeloid leukemia and other cancers.
• Patients with relapsed or refractory acute myeloid leukemia.
• Research institutions and pharmaceutical companies.

Net sellingInsider Activity

The most recent 12 insider filings for Actinium Pharmaceuticals, Inc. break down as 12 sales and 0 purchases. On net that is roughly 381K shares disposed (about $1.9M), a signal worth weighing alongside the fundamentals.

FY2026 estForward Outlook

Wall Street analysts project Actinium Pharmaceuticals, Inc. revenue of about $12.9M for fiscal 2026, with EPS near $-0.85. The estimate reflects 3 contributing analysts.

F-Score 2/9Financial Health

Actinium Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.12 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -51.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -72.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -74.4%, the inverse of the P/E and a quick read on earnings relative to price.

Actinium Pharmaceuticals, Inc. (ATNM) Valuation Context

Valued at $30.20M, ATNM is classified as a micro-cap stock. Relative to its peer group, ATNM's quantitative score of 19/100 is below the peer average of 76/100.

Company Profile

Actinium Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York, United States.

ATNM Financials

ATNM Latest News

ATNM Analyst Consensus

ATNM MoonshotScore

Common Questions About ATNM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources